Journal of Cannabis Research, Год журнала: 2024, Номер 6(1)
Опубликована: Окт. 9, 2024
Studies investigating the association between cannabis use and physical activity have had mixed results. This study provided a population-based assessment while determining how relationship is affected by variables such as legalization status chronic medical conditions.
Язык: Английский
International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(11), С. 5749 - 5749
Опубликована: Май 25, 2024
Neurological disorders present a wide range of symptoms and challenges in diagnosis treatment. Cannabis sativa, with its diverse chemical composition, offers potential therapeutic benefits due to anticonvulsive, analgesic, anti-inflammatory, neuroprotective properties. Beyond cannabinoids, cannabis contains terpenes polyphenols, which synergistically enhance pharmacological effects. Various administration routes, including vaporization, oral ingestion, sublingual, rectal, provide flexibility treatment delivery. This review shows the efficacy managing neurological such as epilepsy, neurodegenerative diseases, neurodevelopmental disorders, psychiatric painful pathologies. Drawing from surveys, patient studies, clinical trials, it highlights alleviating symptoms, slowing disease progression, improving overall quality life for patients. Understanding mechanisms can open up possibilities using this plant individual needs.
Язык: Английский
Процитировано
8
BMC Psychiatry, Год журнала: 2024, Номер 24(1)
Опубликована: Авг. 8, 2024
Abstract Background Major Depressive Disorder (MDD) and Alcohol Use (AUD) are two high-prevalent conditions where the Endocannabinoid system (ECS) is believed to play an important role. The ECS regulates how different neurotransmitters interact in both disorders, which crucial for controlling emotions responses stress reward stimuli. Measuring peripheral endocannabinoids (eCBs) human serum plasma can help overcome limitations of detecting endocannabinoid levels brain. This systematic review aims identify eCBs patients with MDD and/or AUD find use as diagnostic, prognostic biomarkers, potential therapeutic targets. Methods We conducted a literature search according Preferred Reporting Items Systematic Reviews Meta-Analysis (PRISMA) guidelines from earliest manuscript until October 22, 2023, three electronic databases. included studies adults who had current diagnosis evaluated or endocannabinoids. carefully considered known variables that may affect levels. Results 17 articles this review, measured 170 359 patients. Stressors increase 2-arachidonyl-glycerol (2-AG) concentrations, 2-AG be particular feature depression severity chronicity. Anxiety symptoms negatively correlated anandamide (AEA) AEA significantly increases during early abstinence AUD. Studies suggest negative correlation between Oleoylethanolamide (OEA) length They also show significant OEA fatty acid amide hydrolase (FAAH) activity. Eicosapentaenoylethanolamide (EPEA) clinical remission rates depression. Included such gender, chronicity, symptom severity, comorbid psychiatric symptoms, case AUD, stress-inducibility eCBs. Conclusions highlights role plays Peripheral appear useful biomarkers these further research Using accessible biological samples blood well-designed develop novel therapies disorders.
Язык: Английский
Процитировано
5
International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(22), С. 11909 - 11909
Опубликована: Ноя. 6, 2024
The endocannabinoid system (ECS) is a lipid signaling involved in numerous physiological processes, such as endocrine homeostasis, appetite control, energy balance, and metabolism. ECS comprises endocannabinoids, their cognate receptors, the enzymatic machinery that tightly regulates levels within tissues. This has been identified various organs, including brain liver, multiple mammalian non-mammalian species. However, information regarding sex-specific regulation of remains limited, even though increasing evidence suggests interactions between sex steroid hormones may ultimately modulate hepatic metabolism homeostasis. Within this framework, we will review sexual dimorphism animal models, providing crosstalk endocannabinoids via different metabolic pathways. Additionally, underscore importance understanding how endocrine-disrupting chemicals exogenous cannabinoids influence ECS-dependent pathways manner.
Язык: Английский
Процитировано
5
Neuroscience & Biobehavioral Reviews, Год журнала: 2023, Номер 155, С. 105439 - 105439
Опубликована: Окт. 27, 2023
Язык: Английский
Процитировано
10
Molecular Neurobiology, Год журнала: 2024, Номер unknown
Опубликована: Июнь 10, 2024
Язык: Английский
Процитировано
4
Acta Neuropsychiatrica, Год журнала: 2023, Номер 36(5), С. 287 - 298
Опубликована: Сен. 8, 2023
Abstract Early flow cytometry studies revealed T cell activation in major depressive disorder (MDD). MDD is characterised by of the immune-inflammatory response system (IRS) and compensatory immunoregulatory (CIRS), including deficits regulatory (Treg) cells. This study examines number cannabinoid type 1 (CB1) 2 (CB2) receptor-bearing T/B lymphocytes MDD, effects vitro cannabidiol (CBD) administration on CB1/CB2-bearing immunocytes. Using cytometry, we determined percentage CD20+CB2+, CD3+CB2+, CD4+CB2+, CD8+CB2+ FoxP3+CB1+ cells 19 healthy controls 29 patients 5 conditions: baseline, stimulation with anti-CD3/CD28 or without 0.1 µg/mL, 1.0 10.0 µg/mL CBD. CB2+ was significantly higher CD20+ than CD3+ CD4+ CD 8+ Stimulation anti-CD3/CD8 increases CB2-bearing CD3+, CD8+ cells, as well CB1-bearing FoxP3+ There an inverse association between reduced IRS profiles, M1 macrophage, helper-(Th)-1 Th-17 phenotypes. lowered basal CB1+% CB2+%. 33.2% variance depression phenome (including severity depression, anxiety current suicidal behaviours) explained % (positively) CB2+% (inversely). All five immune populations were increased 10 CBD administration. Reductions /CD4+ contribute to homoeostasis while CD20+CB2+% may pathophysiology activating T-independent humoral immunity.
Язык: Английский
Процитировано
9
ACS Omega, Год журнала: 2024, Номер 9(39), С. 40632 - 40643
Опубликована: Сен. 19, 2024
Cannabidiol (CBD) has demonstrated its potential to enhance depression treatment through various biological pathways. However, the application of CBD is significantly impeded by polymorphic nature, limited water solubility, and hepatic first-pass metabolism. To improve chemical stability nanostructured lipid carriers loaded with (CBD-NLCs) were developed using a hot-melt emulsification method optimized response surface methodology (RSM). The process parameters four-factor three-level Box-Behnken experimental design consisting 29 experiments. CBD-NLCs formulated characterized, demonstrating desirable properties, including mean particle size 54.33 nm, PDI value 0.118, zeta -29.7 mV, an impressive encapsulation efficiency rate 87.58%. nanoparticles found possess approximately spherical shape, as revealed scanning transmission electron microscopy. studies have that effectively mitigated photodegradation exhibited stable behavior for 42 days when stored. displayed biphasic release profile characterized initial burst (over 50% released within 20 min) followed subsequent gradual sustained release, aligned first-order kinetics Fickian diffusion. These findings demonstrate suitability this formulation carrier in food fortification pharmaceutical applications.
Язык: Английский
Процитировано
3
Acta Pharmacologica Sinica, Год журнала: 2025, Номер unknown
Опубликована: Фев. 5, 2025
Язык: Английский
Процитировано
0
Cellular Signalling, Год журнала: 2025, Номер unknown, С. 111653 - 111653
Опубликована: Фев. 1, 2025
Язык: Английский
Процитировано
0
Cuadernos de Educación y Desarrollo, Год журнала: 2025, Номер 17(2), С. e7635 - e7635
Опубликована: Фев. 25, 2025
A cicatrização de feridas e o manejo da dor pós-cirúrgica são desafios significativos na prática clínica. O canabidiol (CBD), um fitocanabinoide não psicoativo planta Cannabis sativa, tem emergido como uma opção terapêutica promissora devido às suas propriedades anti-inflamatórias, analgésicas regenerativas. Este artigo revisa as evidências científicas sobre uso do CBD nas diferentes fases feridas—incluindo inflamação, proliferação remodelação—e seu potencial para aliviar a pós-cirúrgica. atua principalmente por meio modulação sistema endocanabinoide (ECS), regulando inflamação promovendo regeneração tecidual. Sua aplicação tópica demonstrado reduzir formação cicatrizes acelerar cicatrização, além possuir antimicrobianas que ajudam prevenir infecções. No dor, pode necessidade opioides, minimizando os riscos dependência outros efeitos colaterais. Apesar terapêutico, transição clínica exige ensaios clínicos rigorosos confirmar eficácia segurança CBD, padronização das formulações vias administração. Conclui-se grande revolucionar tratamentos melhorando resultados qualidade vida dos pacientes.
Процитировано
0